Free Trial

Faron Pharmaceuticals Oy (FARN) Competitors

Faron Pharmaceuticals Oy logo
GBX 207 +4.50 (+2.22%)
As of 07/25/2025 09:54 AM Eastern

FARN vs. ERGO, SLN, PRTC, OXB, HZD, VRP, ARIX, BVXP, CIR, and 4BB

Should you be buying Faron Pharmaceuticals Oy stock or one of its competitors? The main competitors of Faron Pharmaceuticals Oy include Ergomed (ERGO), Silence Therapeutics (SLN), PureTech Health (PRTC), Oxford Biomedica (OXB), Horizon Discovery Group plc (HZD.L) (HZD), Verona Pharma plc (VRP.L) (VRP), Arix Bioscience (ARIX), Bioventix (BVXP), Circassia Group (CIR), and 4basebio (4BB). These companies are all part of the "biotechnology" industry.

Faron Pharmaceuticals Oy vs. Its Competitors

Ergomed (LON:ERGO) and Faron Pharmaceuticals Oy (LON:FARN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership, media sentiment and dividends.

In the previous week, Ergomed's average media sentiment score of 0.00 equaled Faron Pharmaceuticals Oy'saverage media sentiment score.

Company Overall Sentiment
Ergomed Neutral
Faron Pharmaceuticals Oy Neutral

Ergomed has higher revenue and earnings than Faron Pharmaceuticals Oy. Faron Pharmaceuticals Oy is trading at a lower price-to-earnings ratio than Ergomed, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ergomed£152.09M0.00£15M£0.29N/A
Faron Pharmaceuticals OyN/AN/A-£60.23M-£37.39-5.54

Ergomed has a net margin of 9.87% compared to Faron Pharmaceuticals Oy's net margin of 0.00%. Ergomed's return on equity of 18.08% beat Faron Pharmaceuticals Oy's return on equity.

Company Net Margins Return on Equity Return on Assets
Ergomed9.87% 18.08% 10.16%
Faron Pharmaceuticals Oy N/A 0.46%-70.00%

Ergomed has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500. Comparatively, Faron Pharmaceuticals Oy has a beta of 0.36, meaning that its share price is 64% less volatile than the S&P 500.

71.1% of Ergomed shares are held by institutional investors. Comparatively, 10.7% of Faron Pharmaceuticals Oy shares are held by institutional investors. 18.2% of Ergomed shares are held by insiders. Comparatively, 31.8% of Faron Pharmaceuticals Oy shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Ergomed beats Faron Pharmaceuticals Oy on 9 of the 10 factors compared between the two stocks.

Get Faron Pharmaceuticals Oy News Delivered to You Automatically

Sign up to receive the latest news and ratings for FARN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FARN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FARN vs. The Competition

MetricFaron Pharmaceuticals OyBiotechnology IndustryMedical SectorLON Exchange
Market Cap£277.90M£136.77M£5.70B£3.02B
Dividend YieldN/A3.74%4.58%5.02%
P/E Ratio-5.543.7828.39160.65
Price / SalesN/A4,471.55427.44278,114.26
Price / Cash20.0013.1936.2227.97
Price / Book0.1142.328.674.70
Net Income-£60.23M-£90.99M£3.25B£5.90B
7 Day Performance1.25%4.86%4.30%0.40%
1 Month Performance8.95%8.36%10.57%7.09%
1 Year Performance35.74%195.82%35.68%73.21%

Faron Pharmaceuticals Oy Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FARN
Faron Pharmaceuticals Oy
N/AGBX 207
+2.2%
N/A+45.8%£277.90MN/A-5.5434
ERGO
Ergomed
N/AN/AN/AN/A£701.00M£152.09M4,641.386
SLN
Silence Therapeutics
N/AN/AN/AN/A£480.35M£11.35M-11.01100High Trading Volume
PRTC
PureTech Health
1.922 of 5 stars
GBX 137
+2.7%
GBX 455
+232.1%
-17.7%£411.52M£521.32K-5.62300News Coverage
High Trading Volume
OXB
Oxford Biomedica
N/AGBX 357
-1.5%
GBX 390
+9.2%
+9.9%£379.50M£98.31M-2.65891Gap Down
HZD
Horizon Discovery Group plc (HZD.L)
N/AN/AN/AN/A£302.98M£54.63M-33.55416
VRP
Verona Pharma plc (VRP.L)
N/AN/AN/AN/A£228MN/A-1.6822Gap Up
ARIX
Arix Bioscience
N/AN/AN/AN/A£183.73M£14.16M1,290.919
BVXP
Bioventix
N/AGBX 2,738
+0.5%
N/A-37.3%£143.37M£13.65M17.7112News Coverage
Gap Down
CIR
Circassia Group
N/AN/AN/AN/A£142.66M£27.90M3,400.00111Gap Down
4BB
4basebio
N/AGBX 1,000
flat
GBX 1,600
+60.0%
-35.1%£128.10M£311K-1,282.05101Gap Up
High Trading Volume

Related Companies and Tools


This page (LON:FARN) was last updated on 7/26/2025 by MarketBeat.com Staff
From Our Partners